Navigation Links
YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
Date:10/29/2009

tiated from other approaches using opioids because patients are able to individually control the analgesia required for their differing intensities of pain. AeroLEF met all endpoints in a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE YM BioSciences Inc.


'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... St Louis, MO (PRWEB) July 28, 2014 ... tools, software, and services that bring the power of ... for the inaugural Appistry Pipeline Challenge . ... Callum Bell, president of the National Center for Genome ... Children’s Mercy Hospitals and Clinics of Kansas City. Rounding ...
(Date:7/28/2014)... San Francisco, California (PRWEB) July 28, 2014 ... reach USD 604.40 billion by 2020, according to a ... scope coupled with the rising demand for effective vaccines ... to patients with unmet medical needs is expected to ... addition, the need to enhance agricultural productivity via the ...
(Date:7/28/2014)... Texas and COLLEGE STATION, Texas , ... hotel theatlashotel.com will be a 177-key, 4-star boutique ... in Bryan , Texas.  Photo ... As the first hotel within ATLAS ... include 177 rooms, a mixture of standard rooms and suites, a ...
(Date:7/28/2014)... The National Model Aviation Museum, located at the ... announce that it has been granted full civilian museum ... Air Force. , The certification is the culmination of ... with an on-site inspection by Sarah Sessions, Museum Certification ... National Museum of the United States Air Force , ...
Breaking Biology Technology:Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 3Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 4AMA’s National Model Aviation Museum Granted Full Civilian Museum Certification by the National Museum of the United States Air Force 2
... (NYSE: SGP ) will provide a live ... Ph.D., executive vice president and president, Schering-Plough Research Institute, ... San Francisco on Monday, Jan. 12, at approximately 3:30 ... to talk about the company,s R&D pipeline and select ...
... 9 Endo Pharmaceuticals (Nasdaq: ENDP ) announced ... Endo, will present a corporate update at the J.P. Morgan ... 10:30 a.m. Pacific Time. The conference will be held ... live audio Webcast of the presentation may be accessed on ...
... Ireland, January 9 Azur Pharma Limited ... exclusive U.S. marketing rights,for Niravam(R) (alprazolam orally ... (baclofen,orally disintegrating tablets) and Fluxid(TM) (famotidine orally,disintegrating ... were not,disclosed. , ...
Cached Biology Technology:Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference 2Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB 2
(Date:7/25/2014)... Before the colonial era, 100,000s of people lived on ... cultures manipulated fire to control the availability of plants ... tribes continue to use fire to maintain desired habitat ... the U.S. Forest Service,s Pacific Southwest Station, will lead ... National Wildfire Refuge during the Ecological Society of America,s ...
(Date:7/25/2014)... study published online in the International Journal of ... to preventing cervical cancer based on findings showing successful ... of a discrete population of cells in the cervix. ... looked at squamocolumnar junction cells, or SCJ cells. These ... implicated as the origins of cervical cancer. A research ...
(Date:7/25/2014)... the way for the development of new lines of barley ... production is second only to wheat with 7-8 million tonnes ... diseases of barley. , Senior Research Scientist Dr Alan Little ... the cell walls of barley plants that block the penetration ... the ARC Centre of Excellence in Plant Cell Walls in ...
Breaking Biology News(10 mins):Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3Clearing cells to prevent cervical cancer 2New hope for powdery mildew resistant barley 2
... new role for a key cancer protein, a finding that ... variety of tumors. Many cancers are driven in part ... to escape growth controls and proliferate abnormally. In the new ... , researchers discovered that cyclin D1 also helps cancer cells ...
... by the Biotechnology and Biological Sciences Research Council (BBSRC)-led ... an enzyme in bacteria which could be used to ... in the 14 June Issue of the American Chemical ... out by teams at the Universities of Warwick and ...
... (June 9, 2011) − Mice born to mothers who are ... to develop intestinal tumors, report scientists at the Jean Mayer ... Tufts University. Previous research in humans and mice ... the prevention of colorectal cancer. Using a mouse model of ...
Cached Biology News:Cancer protein discovery may aid radiation therapy 2Cancer protein discovery may aid radiation therapy 3First wood-digesting enzyme found in bacteria could boost biofuel production 2B vitamins in mother's diet reduce colorectal cancer risk in offspring 2
... Proteolytic degradation is critical to the ... and regulatory proteins as important and ... metabolism, heat shock and stress response, ... receptors and ion channels, cell cycle ...
... standard for whole-blood clinical diagnostic work in ... less, this analyzer makes precise glucose measurements ... precise lactate measurements of whole blood, plasma, ... option allows you to have glucose results ...
... The first high-density serum biomarker chip to ... proteins. An antibody chip containing 120 human ... that enables biomarker discovery scientists to study ... benefits of therapy and the likelihood of ...
... description: The Costar strip ejector is a ... of Costar strips from their holder. Linkage: ... number, created to easily match Cornings product ... order under the old Sigma-Aldrich number (Z71,314-7) ...
Biology Products: